Technology evaluation: ING-1, XOMA.
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors. In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated.